The missing link between data generation and unleashing it to power automation often lies in well-governed cloud infrastructure.
- Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
- The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-Oncology
- Spine Care Redefined: Autologous Cell Therapy For Degenerative Disc Disease
- A Multi-Agent Audit Intelligence Framework For CDMO Quality Oversight
- Why Contamination Control By Design Should Matter To Your CDMO
- Repeating Sanofi's Ballroom Design On Two Continents
- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- Closing The MES Value Gap: Why Technology Isn't The Problem
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
How Can I Increase My Viral Titers And Improve The Percentage Of Full AAVs?
Explore various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.
-
Analyzing Poly(A) Tails Of In Vitro Transcribed RNA
Find out how to achieve reliable IVT mRNA quality. Learn the best practices for precise analysis, including proper sample prep and system optimization for high-resolution results.
-
Raman As A Quality Control Tool For Cell Culture Media Preparation
Explore study results demonstrating how Raman technology easily differentiates between media with similar compositions and detects potential preparation errors that other analysis methods might miss.
-
Rapid Automated Selection Of Mammalian Cell Colonies
Discover how a new technology cultivates mammalian cells into clonal colonies and images them using fluorescent assays to isolate clonal cell populations based on surface protein expression.
-
The Hidden Costs Of Paper Logbooks
Stop losing time and capacity to manual paperwork. Learn how digital workflows eliminate compliance risks and unlock the actionable data needed to optimize life sciences manufacturing.
-
Residual Plasmid Quantification In Gene Therapy Manufacturing Workflows
This article details the design and application of a Plasmid DNA - Kanamycin Resistance Gene (pDNA-KanR) kit for residual plasmid quantification in gene therapy manufacturing.
-
Expansion Of Human Bone Marrow-Derived MSCs
Achieving over 870 million viable, quality mesenchymal stem/stromal cells is possible. This efficient cell culture method scales bone marrow-derived MSCs for clinical needs.
-
Optimizing TFF And SPTFF For High-Concentration mAb Formulations
Discover the critical role of formulation buffer composition in stabilizing monoclonal antibodies during tangential flow filtration, a process involving ultrafiltration and diafiltration under high pressure and shear forces.
-
3D Cell Culture Reveals Undetectable Drug Efficacy In Traditional Systems
Drug discovery now targets cancer stem cells (CSCs) to achieve long-term tumor eradication, which moves beyond traditional chemotherapeutics. Discover an advanced screening platform that better predicts CSC inhibitor efficacy.
-
The Case For Modernizing Small-Volume Aseptic Processing
Tube welding and biosafety cabinets present significant costs and risks for small-volume aseptic processing. Modern single-use aseptic connectors offer a more efficient alternative.
NEWSLETTER ARCHIVE
- 05.22.26 -- Scaling RNA & LNP Manufacturing With Smarter Analytics
- 05.22.26 -- Inside March Biosciences' CD5-Targeting CAR-T Approach
- 05.21.26 -- Advancing Bioprocessing: Perfusion And Process Intensification Across Modalities
- 05.21.26 -- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- 05.20.26 -- Streamlined Lentiviral Characterization And QC With Digital PCR
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections